Literature DB >> 1557419

A 36-base-pair core sequence of locus control region enhances retrovirally transferred human beta-globin gene expression.

J C Chang1, D Liu, Y W Kan.   

Abstract

The locus control region of the human beta-globin cluster consists of four major DNase I hypersensitive sites (HS). When linked to globin genes, the locus control region confers a high level of erythroid-specific expression of these genes in transgenic mice or transfected erythroid cell lines. We have examined the effect of one of these sites, HS2, on human beta-globin gene expression in a murine erythroleukemia cell line (MEL) after retrovirus-mediated gene transfer. We incorporated a 732- or 412-base-pair (bp) segment of HS2 in the retroviral construct carrying the human beta-globin gene. These fragments rendered the viruses unstable as the human beta-globin gene was rearranged or deleted in all the packaging cell lines examined. On the other hand, when a 36-bp fragment containing the NFE-2/AP-1 binding consensus in this region was inserted into the retroviral construct, we recovered 6 stable packaging cell lines of 12 examined, similar in percentage to the construct with the beta-globin gene alone. The virus titers of the packaging cell lines from these two constructs were similar. We infected MEL cells with viruses produced from three packaging cell lines of each of the two constructs and measured the ratio of human beta-globin to mouse alpha-globin mRNA after hexamethylenebisacetamide induction. The overall level of expression increased 2-fold from 6.0% to 12.7% with the addition of this 36-bp enhancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1557419      PMCID: PMC48813          DOI: 10.1073/pnas.89.7.3107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Gene therapy.

Authors:  I M Verma
Journal:  Sci Am       Date:  1990-11       Impact factor: 2.142

2.  Tandem AP-1-binding sites within the human beta-globin dominant control region function as an inducible enhancer in erythroid cells.

Authors:  P A Ney; B P Sorrentino; K T McDonagh; A W Nienhuis
Journal:  Genes Dev       Date:  1990-06       Impact factor: 11.361

3.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

4.  Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S.

Authors:  R L Nagel; R M Bookchin; J Johnson; D Labie; H Wajcman; W A Isaac-Sodeye; G R Honig; G Schilirò; J H Crookston; K Matsutomo
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

5.  Enhancing the efficiency of DNA-mediated gene transfer in mammalian cells.

Authors:  C M Corsaro; M L Pearson
Journal:  Somatic Cell Genet       Date:  1981-09

6.  Human beta-globin locus control region: analysis of the 5' DNase I hypersensitive site HS 2 in transgenic mice.

Authors:  J J Caterina; T M Ryan; K M Pawlik; R D Palmiter; R L Brinster; R R Behringer; T M Townes
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

7.  Synergistic enhancement of globin gene expression by activator protein-1-like proteins.

Authors:  P Moi; Y W Kan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

8.  High-level beta-globin expression after retroviral transfer of locus activation region-containing human beta-globin gene derivatives into murine erythroleukemia cells.

Authors:  U Novak; E A Harris; W Forrester; M Groudine; R Gelinas
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

9.  In vivo protein-DNA interactions at the beta-globin gene locus.

Authors:  T Ikuta; Y W Kan
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

Review 10.  Somatic gene therapy.

Authors:  C Hesdorffer; D Markowitz; M Ward; A Bank
Journal:  Hematol Oncol Clin North Am       Date:  1991-06       Impact factor: 3.722

View more
  21 in total

1.  Nrf2 is essential for protection against acute pulmonary injury in mice.

Authors:  K Chan; Y W Kan
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

2.  Comparison of two kinds of methods to determine the titer of recombinant retrovirus containing beta-globin gene based on G418 selection.

Authors:  W Dong; D Liu; J Li; B Li; Z Guo; C C Liang
Journal:  Mol Biotechnol       Date:  2000-05       Impact factor: 2.695

3.  An Erythroid-Specific Chromatin Opening Element Increases β-Globin Gene Expression from Integrated Retroviral Gene Transfer Vectors.

Authors:  Michael J Nemeth; Christopher H Lowrey
Journal:  Gene Ther Mol Biol       Date:  2004-12

4.  Evaluation of beta-globin gene therapy constructs in single copy transgenic mice.

Authors:  J Ellis; P Pasceri; K C Tan-Un; X Wu; A Harper; P Fraser; F Grosveld
Journal:  Nucleic Acids Res       Date:  1997-03-15       Impact factor: 16.971

Review 5.  Development of gene therapy for thalassemia.

Authors:  Arthur W Nienhuis; Derek A Persons
Journal:  Cold Spring Harb Perspect Med       Date:  2012-11-01       Impact factor: 6.915

6.  Locus control region of the human CD2 gene in a lentivirus vector confers position-independent transgene expression.

Authors:  C M Kowolik; J Hu; J K Yee
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 7.  Gene therapy for hemoglobinopathies: the state of the field and the future.

Authors:  Shanmuganathan Chandrakasan; Punam Malik
Journal:  Hematol Oncol Clin North Am       Date:  2014-04       Impact factor: 3.722

Review 8.  The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges.

Authors:  Michael A Goodman; Punam Malik
Journal:  Ther Adv Hematol       Date:  2016-06-25

9.  Retroviral transfer of a human beta-globin/delta-globin hybrid gene linked to beta locus control region hypersensitive site 2 aimed at the gene therapy of sickle cell disease.

Authors:  K J Takekoshi; Y H Oh; K W Westerman; I M London; P Leboulch
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

Review 10.  Gene therapy for hemoglobinopathies: progress and challenges.

Authors:  Alisa Dong; Stefano Rivella; Laura Breda
Journal:  Transl Res       Date:  2013-01-19       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.